Welcome to our dedicated page for Hims & Hers Health news (Ticker: HIMS), a resource for investors and traders seeking the latest updates and insights on Hims & Hers Health stock.
Hims & Hers Health, Inc. (NYSE: HIMS) is a health and wellness platform that regularly issues news about its digital care offerings, new specialties, and international growth. Company press releases highlight how the Hims and Hers brands use technology to connect customers with personalized care, with updates that span weight management, women’s health, labs and diagnostics, and broader platform developments.
Recent news has focused heavily on weight loss and metabolic health. Hims & Hers has launched a comprehensive Weight Loss Programme in the UK, including the official introduction of the Hers platform there, giving eligible women access to doctor-designed GLP‑1 treatment plans and holistic support for nutrition, movement, and sleep. In Canada, the company is entering the market through the acquisition of Livewell, a digital health platform focused on weight loss treatment, with plans to roll out an accessible, comprehensive weight loss program for Canadian customers.
Another key news theme is women’s health. The Hers platform has introduced a menopause and perimenopause specialty that offers eligible women access to treatment plans tailored to their health history and preferences, including prescription options such as estradiol and progesterone when deemed appropriate by licensed providers. News coverage also includes the launch of Labs, a testing experience that measures biomarkers across areas like heart health, metabolism, hormones, inflammation, and stress, pairing results with doctor-developed action plans.
Investors and followers of HIMS news will also see announcements about strategic acquisitions, such as the definitive agreement to acquire YourBio Health and its virtually painless TAP blood sampling technology, as well as corporate updates like share repurchase authorizations, financial results, leadership appointments, and facility investments. This news page aggregates these developments so readers can monitor how Hims & Hers is expanding its digital health platform, adding new capabilities, and executing its strategy across the United States, Europe, and Canada.
Hims & Hers Health (NYSE:HIMS) announced a major expansion into testosterone treatments through an exclusive collaboration with Marius Pharmaceuticals. The company will launch KYZATREX®, an FDA-approved oral testosterone medication, in 2026, shown to restore testosterone levels in up to 96% of men.
The platform is immediately launching personalized treatment options including compounded enclomiphene and a dual-action treatment combining enclomiphene with tadalafil. The company will also introduce injectable testosterone treatments in 2026. The initiative aims to address the estimated 20 million men in the U.S. affected by low testosterone, offering simplified access through at-home blood testing and licensed provider consultation.
Hims & Hers Health (NYSE:HIMS) reported strong Q2 2025 financial results, with revenue reaching $544.8 million, up 73% year-over-year. The company achieved net income of $42.5 million and Adjusted EBITDA of $82.2 million.
Subscriber base grew to over 2.4 million, representing a 31% increase year-over-year, while monthly online revenue per subscriber improved by 30% to $74. The company maintained its full-year 2025 guidance, projecting revenue between $2.3-2.4 billion and Adjusted EBITDA of $295-335 million.
For Q3 2025, HIMS expects revenue of $570-590 million and Adjusted EBITDA of $60-70 million. The company plans to expand into new specialties and enhance its personalization infrastructure, lab testing capabilities, and international presence.
Hims & Hers Health (NYSE: HIMS) has released compelling data demonstrating the success of its personalized weight loss program featuring GLP-1 treatments. The analysis revealed that customers lost an average of 20.9 pounds (10.3% of initial body weight) within six months, with a remarkable 75% retention rate during the treatment period.
The company's holistic approach combines personalized GLP-1 dosing with 24/7 care team access and comprehensive wellness support. Key metrics include a low 10.3% side effect rate, with only 4.5% reporting intolerable effects. The platform facilitated over 6.7 million customer-care team messages, with 75% of responses delivered within 5 hours. Notably, 97% of customers reported improved overall health, and 73% preferred Hims & Hers' digital health experience over alternatives.
Hims & Hers Health (NYSE: HIMS), the leading health and wellness platform, has scheduled its second quarter 2025 financial results announcement for August 4, 2025, after market close. The company will host a conference call at 5:00 p.m. ET to discuss the results.
Additionally, management will participate in the Canaccord Genuity's 45th Annual Growth Conference on August 13, 2025 in Boston.
Hims & Hers Health (NYSE: HIMS) has announced plans to expand into Canada in 2026, coinciding with the first-ever availability of generic semaglutide globally. This strategic expansion follows the company's recent acquisition of European digital health platform ZAVA.
The expansion aims to address a significant market need, as nearly two-thirds of Canadian adults are overweight or living with obesity. The company plans to offer affordable weight loss treatment through its digital platform, featuring 24/7 access to licensed providers and personalized care plans. Currently, branded semaglutide in Canada costs over C$200 monthly, but generic versions are expected to be available at a significant discount.
Hims & Hers Health (NYSE: HIMS) has launched a new pricing initiative for Wegovy®, offering eligible new customers access to the prescription-only weight loss treatment at $549 per month for 6 months through a limited-time offer. The program includes access to the company's comprehensive weight loss approach, featuring technology-driven solutions and holistic care options.
CEO Andrew Dudum emphasized the company's commitment to increasing healthcare accessibility. The platform continues to provide various weight loss solutions, including medications, oral kits, protein supplements, nutrition kits, and clinically-backed care plans, tailored to customers' needs, goals, and eligibility.
Hims & Hers Health (NYSE: HIMS) has priced an upsized $870 million convertible senior notes offering due 2030, with an additional $130 million option for initial purchasers. The zero-interest notes have an initial conversion price of $70.67 per share, representing a 37.5% premium over the last closing price of $51.40.
The company expects net proceeds of approximately $842.7 million (potentially $968.8 million if the additional option is exercised). The funds will be used to accelerate global expansion through organic growth and strategic acquisitions, enhance AI capabilities, develop diagnostic tools, and advance personalized treatments. About $41.6 million will fund capped call transactions to reduce potential dilution.
Hims & Hers Health (NYSE: HIMS) has appointed Mo Elshenawy as its new Chief Technology Officer, marking a significant step in the company's AI-driven healthcare vision. Elshenawy, former President and CTO at Cruise, brings over 20 years of technology sector experience, including expertise in AI, product development, and engineering.
At Cruise, he led the launch of the first commercial driverless rideshare service in San Francisco. His previous experience includes senior leadership roles at Amazon, where he managed global engineering for ReCommerce and developed retail data analytics platforms. Elshenawy holds more than 10 patents in AI, robotics, and autonomous vehicles.
The appointment aligns with Hims & Hers' strategy to build a next-generation healthcare platform powered by AI, focusing on personalized care delivery at scale. The company plans to expand its MedMatch system and invest in AI to enhance diagnosis and improve health and wellness experiences.